Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13182184 | 0.78 | KDM4E (0.44) | KDM4EALDH1A1ALOX12MAPTNPSR1 | |
| SCHEMBL29018280 | 0.75 | KDM4E (0.45) | KDM4EALDH1A1ALOX12MAPTRAB9A | |
| SCHEMBL11527806 | 0.74 | KDM4E (0.48) | KDM4EALDH1A1ALOX12MAPTL3MBTL1 | |
| SCHEMBL31299898 | 0.74 | KDM4E (0.39) | KDM4EALDH1A1ALOX12MAPTL3MBTL1 | |
| SCHEMBL122496 | 0.74 | KDM4E (0.38) | KDM4EALDH1A1ALOX12MAPTRAB9A | |
| SCHEMBL6324088 | 0.72 | MAPT (0.67) | KDM4EALDH1A1MAPTGAAMEN1 | |
| SCHEMBL26099241 | 0.72 | KDM4E (0.37) | KDM4EALDH1A1ALOX12MAPTMEN1 | |
| SCHEMBL1162244 | 0.72 | KDM4E (0.38) | KDM4EALDH1A1ALOX12MAPTRAB9A | |
| SCHEMBL7749425 | 0.71 | ALDH1A1 (0.38) | KDM4EALDH1A1ALOX12MAPTRAB9A | |
| SCHEMBL16327606 | 0.70 | L3MBTL1 (0.47) | KDM4EALDH1A1ALOX12MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 322 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218050-A1 | Cysteine Engineered Antibodies and Conjugates | GENENTECH, INC. (US) | 2024-07-04 | — | — | US | disclosed |
| EP-3269737-B1 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | GENENTECH INC (US) | 2024-06-19 | — | — | EP | disclosed |
| US-11873330-B2 | Cysteine engineered antibodies and conjugates | GENENTECH, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11866496-B2 | Humanized anti-CD79B antibodies and immunoconjugates and methods of use | GENENTECH, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| EP-4238988-A1 | ANTIBODIES AGAINST SARS-COV-2 AND USES THEREOF | Consejo Superior De Investigaciones Científicas (ES) | 2023-09-06 | — | — | EP | disclosed |
| US-20230227502-A1 | COMPOSITIONS AND METHODS FOR MODULATING MYOSIN SUBFRAGMENT-2 COILED COIL STABILITY AND METHODS FOR USING THEM | UNIV NORTH TEXAS (US) | 2023-07-20 | — | — | US | disclosed |
| EP-4182345-A1 | INTERLEUKIN 11 RECEPTOR ALPHA SUBUNIT (IL11RA) NEUTRALIZING ANTIBODIES AND USES THEREOF | Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) (ES) | 2023-05-24 | — | — | EP | disclosed |
| US-20230130874-A1 | Cysteine Engineered Antibodies and Conjugates | GENENTECH, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| CN-114246952-A | Cysteine engineered antibodies and conjugates | 基因泰克公司 | 2022-03-29 | — | — | CN | disclosed |
| US-20220023437-A1 | HUMANIZED ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2022-01-27 | — | — | US | disclosed |
| WO-2004007537-A2 | MODIFIED ADENOVIRAL FIBER WITH ABLATED TO CELLULAR RECEPTORS | TRANSGENE S.A. (FR) | 2004-01-22 | — | — | WO | disclosed |
| US-20030166549-A1 | Targeting peptides | TRANSGENE S.A. (FR) | 2003-09-04 | — | — | US | disclosed |
| US-20030165477-A1 | Poxvirus with targeted infection specificity | TRANSGENE S.A. (FR) | 2003-09-04 | — | — | US | disclosed |
| US-6562632-B1 | Reactive dye for use as diagnostic tool in the analysis of biological systems | MOLECULAR PROBES, INC. | 2003-05-13 | — | — | US | disclosed |
| WO-2002092554-A1 | COMPLEXES FOR TRANSFERRING SUBSTANCES OF INTEREST INTO A CELL | TRANSGENE S.A. (FR) | 2002-11-21 | — | — | WO | disclosed |
| EP-1254163-A2 | TARGETING PEPTIDES | TRANSGENE S.A. (FR) | 2002-11-06 | — | — | EP | disclosed |
| EP-1146125-A1 | Poxvirus with targeted infection specificity | TRANSGENE S.A. (FR) | 2001-10-17 | — | — | EP | disclosed |
| WO-2001057069-A2 | TARGETING PEPTIDES | TRANSGENE S.A. (FR) | 2001-08-09 | — | — | WO | disclosed |
| US-5798276-A | DETECTING COMPLEMENTARY MEMBER OF SPECIFIC BINDING PAIR USING FLUORESCENT CONJUGATE | MOLECULAR PROBES, INC. (US) | 1998-08-25 | — | — | US | disclosed |
| EP-0196669-A2 | Improved method of conjugating metallothionein to biologically active molecules | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1986-10-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220023437-A1 | HUMANIZED ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | CD99, CD79B, CD47 | KDM4E 1925/4885ALDH1A1 2739/4885ALOX12 3819/4885 |
| US-20230130874-A1 | Cysteine Engineered Antibodies and Conjugates | GCLC, CTH, CBS | KDM4E 4419/4885ALDH1A1 1572/4885ALOX12 4351/4885 |
| US-20240218050-A1 | Cysteine Engineered Antibodies and Conjugates | CTH, LNPEP, CARS1 | KDM4E 1568/4885ALDH1A1 1914/4885ALOX12 4878/4885 |
| US-11873330-B2 | Cysteine engineered antibodies and conjugates | CTH, LNPEP, CARS1 | KDM4E 1568/4885ALDH1A1 1914/4885ALOX12 4878/4885 |
| US-11866496-B2 | Humanized anti-CD79B antibodies and immunoconjugates and methods of use | CD99, CD79B, CD47 | KDM4E 1925/4885ALDH1A1 2739/4885ALOX12 3819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.